SD Biosensor

SD Biosensor EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of SD Biosensor (137310.KS) as of Nov 10, 2026 is -1.39 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 35.15 % — a change of -103.95% (lower).

EBIT/Assets

-1.39 %

YoY

-103.95%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of SD Biosensor is 2024 -1.39 % . Operating Income to Assets Ratio (EBIT/Assets) of SD Biosensor was 2023 35.15 % . It decreases by -103.95% lower compared to the previous year.

The SD Biosensor EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
1.39 KRW
Jan 1, 2020
50.51 KRW
Jan 1, 2021
45.39 KRW
Jan 1, 2022
35.15 KRW
Jan 1, 2024
-1.39 KRW
The SD Biosensor EBIT/Assets history
YEAREBIT/AssetsYoY
-1.39 %-103.95%
35.15 %-22.56%
45.39 %-10.13%
50.51 %+3,526.42%
1.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SD Biosensor Stock analysis

What does SD Biosensor do? SD Biosensor Inc generates revenue through the development and manufacturing of cholesterol and blood glucose testing equipment. The company sells rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, and enzyme immunological reaction diagnosis products. These products are distributed domestically and internationally, targeting healthcare providers and consumers in the immunochemical, molecular, and point-of-care diagnosis sectors. The firm focuses on self blood glucose measurement and other diagnostic solutions for medical use. The company's product portfolio includes POCTs, which are used for point-of-care testing in medical settings. SD Biosensor Inc's offerings serve both the domestic market and overseas markets, with a strong emphasis on diagnostic equipment for healthcare applications. Their business model relies on the sale of these specialized medical devices to hospitals, clinics, and individual consumers seeking home health monitoring solutions. Revenue streams are derived from the research, development, and sale of diagnostic products, including immunochemical and molecular diagnosis tools. The firm's products are designed for use in clinical and self-testing environments, supporting both professional healthcare services and personal health management. SD Biosensor Inc's market segments include healthcare institutions and end-users requiring diagnostic testing for cholesterol, blood glucose, and other medical conditions. SD Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SD Biosensor stock

Operating Income to Assets Ratio (EBIT/Assets) of SD Biosensor is -1.39 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of SD Biosensor changed from 35.15 % to -1.39 %, representing a -103.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) SD Biosensor since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s SD Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SD Biosensor

All Key Metrics — SD Biosensor